The DUX4 protein is a co-repressor of the progesterone and glucocorticoid nuclear receptors.
Female
Pregnancy
Animals
Muscular Dystrophy, Facioscapulohumeral
/ genetics
Glucocorticoids
Progesterone
Homeodomain Proteins
/ genetics
Co-Repressor Proteins
Receptors, Glucocorticoid
/ genetics
Nuclear Localization Signals
Placenta
/ metabolism
Transcription Factors
Receptors, Cytoplasmic and Nuclear
Mammals
DUX4
co-regulator
facioscapulohumeral muscular dystrophy
glucocorticoids
hormone nuclear receptor
progesterone
Journal
FEBS letters
ISSN: 1873-3468
Titre abrégé: FEBS Lett
Pays: England
ID NLM: 0155157
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
28
05
2022
received:
24
01
2022
accepted:
28
05
2022
pubmed:
7
6
2022
medline:
27
10
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
DUX4 is a transcription factor required during early embryonic development in placental mammals. In this work, we provide evidence that DUX4 is a co-repressor of nuclear receptors (NRs) of progesterone (PR) and glucocorticoids (GR). The DUX4 C-ter and N-ter regions, including the nuclear localization signals and homeodomain motifs, contribute to the co-repressor activity of DUX4 on PR and GR. Immunoprecipitation studies, using total protein extracts of cells expressing tagged versions of DUX4 and GR, support that these proteins are physically associated. Our studies suggest that DUX4 could modulate gene expression by co-regulating the activity of hormone NRs. This is the first report highlighting a potential endocrine role for DUX4.
Identifiants
pubmed: 35662006
doi: 10.1002/1873-3468.14416
doi:
Substances chimiques
Glucocorticoids
0
Progesterone
4G7DS2Q64Y
Homeodomain Proteins
0
Co-Repressor Proteins
0
Receptors, Glucocorticoid
0
Nuclear Localization Signals
0
Transcription Factors
0
Receptors, Cytoplasmic and Nuclear
0
Banques de données
RefSeq
['NP_001280727.1', 'XM_006519079.1', 'XP_038955305.1', 'XM_001917890.1', 'XM_038653638.1', 'XP_026942273.1', 'XP_017900378.1', 'XM_010600793.2']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2644-2658Subventions
Organisme : NICHD NIH HHS
ID : P50 HD060848
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD060848
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS101166
Pays : United States
Informations de copyright
© 2022 Federation of European Biochemical Societies.
Références
Hewitt JE, Lyle R, Clark LN, Valleley EM, Wright TJ, Wijmenga C, et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystropothhy. Hum Mol Genet. 1994;3(8):1287-95.
Gabriëls J, Beckers MC, Ding H, De Vriese A, Plaisance S, Van Der Maarel SM, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene. 1999;236(1):25-32.
Snider L, Geng LN, Lemmers RJLF, Kyba M, Ware CB, Nelson AM, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 2010;6(10):1-14.
Whiddon JL, Langford AT, Wong CJ, Zhong JW, Tapscott SJ. Conservation and innovation in the DUX4-family gene network. Nat Genet. 2017;49(6):935-40.
Hendrickson PG, Doráis JA, Grow EJ, Whiddon JL, Lim JW, Wike CL, et al. Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons. Nat Genet. 2017;49(6):925-34.
De Iaco A, Planet E, Coluccio A, Verp S, Duc J, Trono D. DUX-family transcription factors regulate zygotic genome activation in placental mammals. Nat Genet. 2017;49(6):941-5.
De Iaco A, Verp S, Offner S, Grun D, Trono D. DUX is a non-essential synchronizer of zygotic genome activation. Developmental. 2020;147(2):1-16.
Chen Z, Zhang Y. Loss of DUX causes minor defects in zygotic genome activation and is compatible with mouse development. Nat Genet. 2019;51(6):947-51.
Bosnakovski D, Gearhart MD, Ho Choi S, Kyba M. Dux facilitates post-implantation development, but is not essential for zygotic genome activation. Biol Reprod. 2021;104(1):83-93.
Guo M, Zhang Y, Zhou J, Bi Y, Xu J, Xu C, et al. Precise temporal regulation of Dux is important for embryo development. Cell Res. 2019;29(11):956-9.
Das S, Chadwick BP. Influence of repressive histone and DNA methylation upon D4Z4 transcription in non-myogenic cells. PLoS One. 2016;11(7):1-26.
Gannon OM, Long LM, Saunders NA. DUX4 is derepressed in late-differentiating keratinocytes in conjunction with loss of H3K9me3 epigenetic repression. J Invest Dermatol. 2016;136(6):1299-302.
Kowaljow V, Marcowycz A, Ansseau E, Conde CB, Sauvage S, Mattéotti C, et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord. 2007;17(8):611-23.
Campbell AE, Belleville AE, Resnick R, Shadle SC, Tapscott SJ. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle. Hum Mol Genet. 2018;27(R2):153-62.
Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387(6634):733-6.
Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet. 2010;11(2):109-23.
Corona ED, Jacquelin D, Gatica L, Rosa AL. Multiple protein domains contribute to nuclear import and cell toxicity of DUX4, a candidate pathogenic protein for facioscapulohumeral muscular dystrophy. PLoS One. 2013;8(10):1-11.
Proietti CJ, Béguelin W, Flaqué MCD, Cayrol F, Rivas MA, Tkach M, et al. Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. Steroids. 2011;76(4):381-92.
Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, Lange CA. The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol. 2010;24(11):2126-38.
Ansseau E, Domire JS, Wallace LM, Eidahl JO, Guckes SM, Giesige CR, et al. Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing α D4Z4 repeat with flanking genomic sequences. PLoS One. 2015;10(3):1-17.
Ansseau E, Eidahl JO, Lancelot C, Tassin A, Matteotti C, Yip C, et al. Homologous transcription factors DUX4 and DUX4c associate with cytoplasmic proteins during muscle differentiation. PLoS One. 2016;11(1):1-37.
Belot M, Abdennebi-najar L, Taı J, Emilie D. Progesterone reduces the migration of mast cells toward the chemokine stromal cell-derived factor-1/CXCL12 with an accompanying decrease in CXCR4 receptors. Am J Physiol Endocrinol Metab. 2007;5:1410-7.
Gyu-Chun L, In-Myung Y, Byoung-Joon K, Jeong-Taek W, Sung-Woon K, Jin-Woo K, et al. Identification of glucocorticoid response element of the rat TRH gene. Korean J Intern Med. 1996;11(2):138-44.
Leidenroth A, Hewitt JE. A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene. BMC Evol Biol. 2010;10(1):1-13.
Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. Bioinform. 2009;25(9):1189-1191.
Mitsuhashi H, Ishimaru S, Homma S, Yu B, Honma Y, Beermann ML, et al. Functional domains of the FSHD-associated DUX4 protein. Biol Open. 2018;7(4):1-11.
Lee JK, Bosnakovski D, Toso EA, Dinh T, Banerjee S, Bohl TE, et al. Crystal structure of the double homeodomain of DUX4 in complex with DNA. Cell Rep. 2018;25(11):2955-62.
Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Genet. 2005;6(1):5998-6003.
Xu L, Glass K, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Genet Dev. 1999;9:140-7.
Truss M, Bartsch J, Schelbert A, Haché RJG, Beato M. Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. EMBO J. 1995;14(8):1737-51.
Nardulli AM, Katzenellenbogen BS. Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology. 1988;122(4):1532-40.
Zhang Y, Lee JK, Toso EA, Lee JS, Choi SH, Slattery M, et al. DNA-binding sequence specificity of DUX4. Skelet Muscle. 2016;6(1):1-11.
Geng LN, Yao Z, Snider L, Fong AP, Cech JN, Young JM, et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell. 2012;22(1):38-51.
Abdel-hafiz HA, Dudevoir ML, Perez D, Abdel-hafiz M. SUMOylation regulates transcription by the progesterone receptor a isoform in a target gene. Diseases. 2018;6(5):1-16.
Watson PJ, Fairall L, Schwabe JWR. Nuclear hormone receptor co-repressors: structure and function. Mol Cell Endocrinol. 2012;348(2):440-9.
Choi SH, Gearhart MD, Cui Z, Bosnakovski D, Kim M, Schennum N, et al. DUX4 recruits P300/CBP through its C-terminus and induces global H3K27 acetylation changes. Nucleic Acids Res. 2016;44(11):5161-73.
Ansseau E, Laoudj-Chenivesse D, Marcowycz A, Tassin A, Vanderplanck C, Sauvage S, et al. DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation. PLoS One. 2009;4(10):1-11.
Vanderplanck C, Tassin A, Ansseau E, Charron S, Wauters A, Lancelot C, et al. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei. Skelet Muscle. 2018;8(1):1-16.
Beckers MC, Gabriëls J, Van Der Maarel S, De Vriese A, Frants RR, Collen D, et al. Active genes in Junk DNA? Characterization of DUX genes embedded within 3.3 kb repeated elements. Gene. 2001;264(1):51-7.
Wang LH, Tawil R. Current therapeutic approaches in FSHD. J Neuromuscul Dis. 2020;8(3):441-51.
Hiroyuki H, Tetsuya T, Nobuaki K. Structure and functions of powerful transactivators: VP16, MyoD and FoxA. Int J Dev Biol. 2010;49(18):1841-50.
Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995;377(6548):397-404.
Zhang J, Kalkum M, Chait BT, Roeder RG. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 2002;9(3):611-23.
Wong MM, Guo C, Zhang J. Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation. Am J Clin Exp Urol. 2014;2(3):169-87.
Astapova I. Role of co-regulators in metabolic and transcriptional actions of thyroid hormone. J Mol Endocrinol. 2016;56(3):R73-97.
Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol. 2005;6(7):542-54.
Oñate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270(5240):1354-7.
Chrivia JC, Kwok RPS, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature. 1993;365(6449):855-9.
Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, et al. Molecular cloning and functional analysis of the Adenovirus E1A-associated 300-KD protein (P300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 1994;8(8):869-84.
Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377(6548):454-7.
Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122(6):835-47.
Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARa. Eur J Med Chem. 2002;94:229-36.
Yang J, Anishchenko I, Park H, Peng Z, Ovchinnikov S, Baker D. Improved protein structure prediction using predicted interresidue orientations. Proc Natl Acad Sci USA. 2020;117(3):1496-503.
Perissi V, Staszewski LM, Mcinerney EM, Kurokawa R, Krones A, Rose DW, et al. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 1999;13(24):3198-208.
Gurevich I, Flores AM, Aneskievich BJ. Corepressors of agonist-bound nuclear receptors. Toxicol Appl Pharmacol. 2009;49(18):1841-50.
Tonini MMO, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord. 2004;14(1):33-8.
Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RCM, Passos-bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet. 1998;77:155-61.
Teveroni E, Pellegrino M, Sacconi S, Calandra P, Cascino I, Farioli-Vecchioli S, et al. Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. J Clin Invest. 2017;127(4):1531-45.
Hangül C, Bozkurt S, Bilge U, Özdem S, Altunbaş H, Uysal H, et al. The ratios of estradiol and progesterone to testosterone influence the severity of facioscapulohumeral muscular dystrophy. Neurol Sci Neurophysiol. 2020;37(4):190-6.
Banerji CRS, Cammish P, Evangelista T, Zammit PS, Straub V, Marini-Bettolo C. Facioscapulohumeral muscular dystrophy 1 patients participating in the UKFSHD Registry can be subdivided into 4 patterns of self-reported symptoms. Neuromuscul Disord. 2020;30(4):315-28.
Hangul C, Celik EG, Kaya H, Eroglu O, Uysal H, Karauzum SB. Estradiol differentially regulates DUX4, β-catenin and PAX3/PAX7 in primary myoblasts of facioscapulohumeral muscular dystrophy patients. Turkish J Biochem. 2021;46:435-44.
Arahata K, Ishihara T, Fukunaga H, Orimo S, Lee JEH, Goto K, et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl. 1995;2:S56-66.
Molnár M, Diószeghy P, Mechler F. Inflammatory changes in facioscapulohumeral muscular dystrophy. Eur Arch Psychiatry Clin Neurosci. 1991;241:105-8.
Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle. 2014;4(1):1-15.
Banerji CRS, Macura MP, Zammit PS. DUX4-expressing immortalised FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation. Hum Mol Genet. 2020;29(14):2285-99.
Choi J, Park Y, Shin J, Lee C, Kim D, Kim D. Extensive inflammatory reaction in facioscapulohumeral muscular dystrophy. Ann Clin Neurophysiol. 2017;19(2):141-4.
Wang LH, Friedman SD, Shaw D, Snider L, Wong C, Budech CB, et al. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD. Hum Mol Genet. 2019;28(3):476-86.
Frisullo G, Frusciante R, Nociti V, Tasca G, Renna R, Iorio R, et al. CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol. 2011;31(2):155-66.
Knopp P, Krom YD, Banerji CRS, Panamarova M, Moyle LA, den Hamer B, et al. DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis. J Cell Sci. 2016;129(20):3816-31.
Weintraub H, Dwarki VJ, Verma I, Davis R, Hollenberg S, Snider L, et al. Muscle-specific transcriptional activation by MyoD. Genes Dev. 1991;5:1377-86.